The 2020 Shijiazhuang International Biotechnology and Pharmaceutical R&D Cloud Summit was held

The 2020 Shijiazhuang International Biotechnology and Pharmaceutical R&D Cloud Summit, focusing on pharmaceutical innovation and promoting industrial development together, was grandly held on September 24th in the provincial capital Shijiazhuang. This summit is hosted by the Science and Technology Bureau of Shijiazhuang City and organized by Hebei Noah Dehui Human Resources Service Co., Ltd. It aims to promote the in-depth development of the biopharmaceutical industry in Shijiazhuang City, Hebei Province, improve the pharmaceutical and health industry chain and innovation chain, and create a biopharmaceutical industry base with regional competitiveness and influence. This event invited 5 international experts in the biopharmaceutical industry, who conducted in-depth discussions on global hot topics such as research and innovation in international biopharmaceutical technology and the biopharmaceutical field. Our company, Shijiazhuang Jirong Pharmaceutical Co., Ltd., participated in this event

2020-09-27

Four draft revisions of pharmaceutical excipient standards are publicly announced!

According to the 2020 edition of the Pharmacopoeia, the inclusion of standards for raw materials, traditional Chinese medicinal materials, and medicinal excipients will be emphasized. The draft for soliciting opinions clearly proposes to further strengthen and improve the pharmacopoeia standard system for pharmaceutical excipients and packaging materials

2020-06-04

The scale of biopharmaceutical excipients in the Asia Pacific region is nearly 800 million US dollars

According to a new report released by market research firm Grand View Research, the Asia Pacific biopharmaceutical excipient market was approximately $473.72 million in 2017 and is expected to reach $791.4 million by 2025. During the forecast period, this market will grow at a compound annual growth rate (CAGR) of 6.63%.

2020-06-04

The National Medical Products Administration has officially issued a document stating that the year-end deadline for consistency evaluation has been extended!

On December 28th, the official website of the National Medical Products Administration released the "Announcement of the National Medical Products Administration on Relevant Matters of Quality and Efficacy Consistency Evaluation of Generic Drugs (No. 102 of 2018)",

2020-06-04